Press Releases
-
Aug 23, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jeffrey Cooper has been promoted to the position of Chief Financial Officer, effective immediately. Mr. Cooper succeeds...
-
Aug 1, 2005Conference Call and Webcast to Be Held Tuesday, August 2, at 12:00 p.m. EDT (18:00 CEST)
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2005. The net loss was $21.3 million ($0.33 per share) for the second quarter of...
-
Aug 1, 2005
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for Orapred ODT(TM) (prednisolone sodium...
-
Jul 14, 2005$59.9 Million of Common Stock Priced
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it plans to publicly offer 8,500,000 shares of its common stock, pursuant to an effective shelf registration statement. In...
-
Jul 5, 2005- New Top Line 2005 Product Revenue Guidance Issued -
BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has eliminated 58 positions, of which 52 were held by personnel responsible for the sale of Orapred(R) (prednisolone...
